FDA Accepts Merck Sugammadex Sodium Injection New Drug Application

Merck’s new drug application resubmission for sugammadex sodium injection has been accepted for review by the FDA.

Advertisement

Neuromuscular blockade, which is used by anesthesiologists to relax muscles during surgery, is revered by the sugammadex sodium injection. Upon approval, this substance would be one of the first medicines of its kind to be used in the U.S. surgical setting.

The FDA previously rejected the NDA in 2008 and requested more data on allergic reactions and bleeding events. The application has now been deemed complete for review.

More Articles on Anesthesia:
CMS Updates Locale Specific Anesthesia Conversion Rate
Novitas Expected to Revise Anesthesia Coverage Limits
Providence Washington Anesthesia Services Announces CME Symposium, Proceeds to Benefit Non-Profit

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.